Top

Published in:

01-02-2023 | Review

Nanoparticles for the treatment of visceral leishmaniasis: review

Authors: Natália Silva de Santana, Luciana Betzler de Oliveira de Siqueira, Tatielle do Nascimento, Ralph Santos-Oliveira, Ana Paula dos Santos Matos, Eduardo Ricci-Júnior

Published in: Journal of Nanoparticle Research | Issue 2/2023

Activate our intelligent search to find suitable subject content or patents.

search-config

AI-assisted search

Off

Abstract

Visceral leishmaniasis is an infectious disease caused by the protozoan Leishmania. Due to the lack of vaccines and the limitations of current treatment (toxicity, serious adverse effects, and high cost), new therapeutic options must be developed. This work aims to perform a systematic review focusing on studies that use nanoparticles to treat visceral leishmaniasis, with in vivo tests to evaluate the antileishmanial effect. The search was carried out between January 2011 and August 2021 in the PubMed and Web of Science databases, using the keywords “visceral leishmaniasis and nanoparticles and in vivo.” The articles were selected through inclusion and exclusion criteria. After the analysis, 26 articles were selected containing polymeric, lipidic, metallic, and inorganic nanoparticles. As for the nanometric size, the polymeric and lipid nanoparticles showed size ranges from 138 to 377.9 nm and 103.7 to 266.3 nm, respectively. The inorganic nanoparticles had a size of around 140 nm. Also, the metallic nanoparticles showed sizes of 58.6, 134.3, and 142.7 nm. In addition, amphotericin B was the most used drug. In some studies, drug co-encapsulation was performed, which is a future trend, useful to increase the therapeutic efficacy of the treatment. The studies showed that the use of nanoparticles for drug delivery was able to reduce the parasite burden and toxicity. Nanoparticles can increase the efficacy and safety of the treatment, suggesting a promising option for visceral leishmaniasis treatment.

Graphical Abstract

previous article Nanoparticle and nanomaterial involvement during the wound healing process: an update in the field

next article Eudragit®-based nanoparticles for controlled release through topical use

Dont have a licence yet? Then find out more about our products and how to get one now:

Springer Professional "Wirtschaft+Technik"

Online-Abonnement

Mit Springer Professional "Wirtschaft+Technik" erhalten Sie Zugriff auf:

über 102.000 Bücher
über 537 Zeitschriften

aus folgenden Fachgebieten:

Automobil + Motoren
Bauwesen + Immobilien
Business IT + Informatik
Elektrotechnik + Elektronik
Energie + Nachhaltigkeit
Finance + Banking
Management + Führung
Marketing + Vertrieb
Maschinenbau + Werkstoffe
Versicherung + Risiko

Jetzt Wissensvorsprung sichern!

inform now

Springer Professional "Technik"

Online-Abonnement

Mit Springer Professional "Technik" erhalten Sie Zugriff auf:

über 67.000 Bücher
über 390 Zeitschriften

aus folgenden Fachgebieten:

Automobil + Motoren
Bauwesen + Immobilien
Business IT + Informatik
Elektrotechnik + Elektronik
Energie + Nachhaltigkeit
Maschinenbau + Werkstoffe

Jetzt Wissensvorsprung sichern!

inform now

Available only for authorised users

Tiuman TS, Santos AO, Ueda-Nakamura T et al (2011) Recent advances in leishmaniasis treatment. Int J Infect Dis 15:e525–e532. https://doi.org/10.1016/j.ijid.2011.03.021CrossRef

McGwire BS, Satoskar AR (2014) Leishmaniasis: clinical syndromes and treatment. QJM 107:7–14. https://doi.org/10.1093/qjmed/hct116CrossRef

Chávez-Fumagalli MA, Ribeiro TG, Castilho RO et al (2015) New delivery systems for amphotericin B applied to the improvement of leishmaniasis treatment. Rev Soc Bras Med Trop 48:235–242CrossRef

Steverding D (2017) The history of leishmaniasis. Parasit Vectors 10:82. https://doi.org/10.1186/s13071-017-2028-5CrossRef

Volpedo G, Costa L, Ryan N, et al (2019) Nanoparticulate drug delivery systems for the treatment of neglected tropical protozoan diseases. J Venom Anim Toxins Incl Trop Dis 25:e144118. https://doi.org/10.1590/1678-9199-jvatitd-1441-18

Khatik R, Dwivedi P, Khare P et al (2014) Development of targeted 1,2-diacyl-sn-glycero-3-phospho- L-serine-coated gelatin nanoparticles loaded with amphotericin B for improved in vitro and in vivo effect in leishmaniasis. Expert Opin Drug Deliv 11:633–646. https://doi.org/10.1517/17425247.2014.889678CrossRef

Corpas-López V, Díaz-Gavilán M, Franco-Montalbán F et al (2019) A nanodelivered Vorinostat derivative is a promising oral compound for the treatment of visceral leishmaniasis. Pharmacol Res 139:375–383. https://doi.org/10.1016/j.phrs.2018.11.039CrossRef

Bi K, Chen Y, Zhao S et al (2018) Current visceral leishmaniasis research: a research review to inspire future study. Biomed Res Int 2018:1–13. https://doi.org/10.1155/2018/9872095CrossRef

Matos APS, Viçosa AL, Ré MI et al (2020) A review of current treatments strategies based on paromomycin for leishmaniasis. J Drug Deliv Sci Technol 57:101664. https://doi.org/10.1016/j.jddst.2020.101664CrossRef

10.

Kumar R, Sahoo GC, Pandey K et al (2016) Development of PLGA–PEG encapsulated miltefosine based drug delivery system against visceral leishmaniasis. Mater Sci Eng C 59:748–753. https://doi.org/10.1016/j.msec.2015.10.083CrossRef

11.

Singh PK, Jaiswal AK, Pawar VK et al (2018) Fabrication of 3-O-sn-phosphatidyl-L-serine anchored PLGA nanoparticle bearing amphotericin B for macrophage targeting. Pharm Res 35:60. https://doi.org/10.1007/s11095-017-2293-1CrossRef

12.

Costa Lima SA, Silvestre R, Barros D et al (2014) Crucial CD8+ T-lymphocyte cytotoxic role in amphotericin B nanospheres efficacy against experimental visceral leishmaniasis. Nanomedicine Nanotechnology, Biol Med 10:e1021–e1030. https://doi.org/10.1016/j.nano.2013.12.013CrossRef

13.

Singh OP, Gedda MR, Mudavath SL et al (2019) Envisioning the innovations in nanomedicine to combat visceral leishmaniasis: for future theranostic application. Nanomedicine 14:1911–1927. https://doi.org/10.2217/nnm-2018-0448CrossRef

14.

Bayda S, Adeel M, Tuccinardi T et al (2019) The history of nanoscience and nanotechnology: from chemical–physical applications to nanomedicine. Molecules 25:112. https://doi.org/10.3390/molecules25010112CrossRef

15.

Kokila NR, Mahesh B, Roopa KP et al (2022) Thunbergia mysorensis mediated nano silver oxide for enhanced antibacterial, antioxidant, anticancer potential and in vitro hemolysis evaluation. J Mol Struct 1255:132455. https://doi.org/10.1016/j.molstruc.2022.132455CrossRef

16.

Chamaraja NA, Mahesh B, Praveen Kumar CB (2021) Colorimetric detection of chromium (VI) using peroxidase mimetic IONPS with 4- Aminoantipyrene and 3-Aminophenol as a chromogen. Environ Nanotechnology, Monit Manag 16:100471. https://doi.org/10.1016/j.enmm.2021.100471CrossRef

17.

Chamaraja NA, Mahesh B, Rekha ND (2022) Green synthesis of Zn/Cu oxide nanoparticles by Vernicia fordii seed extract: their photocatalytic activity toward industrial dye degradation and their biological activity. Inorg Nano-Metal Chem 1–13. https://doi.org/10.1080/24701556.2022.2069123

18.

Mora-Huertas CE, Fessi H, Elaissari A (2010) Polymer-based nanocapsules for drug delivery. Int J Pharm 385:113–142. https://doi.org/10.1016/j.ijpharm.2009.10.018CrossRef

19.

Akbari M, Oryan A, Hatam G (2017) Application of nanotechnology in treatment of leishmaniasis: a review. Acta Trop 172:86–90. https://doi.org/10.1016/j.actatropica.2017.04.029CrossRef

20.

Cruz R, Calasans-Maia J, Sartoretto S et al (2018) Does the incorporation of zinc into calcium phosphate improve bone repair? A systematic review. Ceram Int 44:1240–1249. https://doi.org/10.1016/j.ceramint.2017.10.157CrossRef

21.

Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372(71):1-13. https://doi.org/10.1136/bmj.n71

22.

Valle IV, Machado ME, da Araújo C, CB, et al (2019) Oral pentamidine-loaded poly(d, l-lactic-co-glycolic) acid nanoparticles: an alternative approach for leishmaniasis treatment. Nanotechnology 30:455102. https://doi.org/10.1088/1361-6528/ab373eCrossRef

23.

Chaubey P, Mishra B, Mudavath SL et al (2018) Mannose-conjugated curcumin-chitosan nanoparticles: efficacy and toxicity assessments against Leishmania donovani. Int J Biol Macromol 111:109–120. https://doi.org/10.1016/j.ijbiomac.2017.12.143CrossRef

24.

Tripathi P, Jaiswal AK, Dube A, Mishra PR (2017) Hexadecylphosphocholine (Miltefosine) stabilized chitosan modified Ampholipospheres as prototype co-delivery vehicle for enhanced killing of L. donovani. Int J Biol Macromol 105:625–637. https://doi.org/10.1016/j.ijbiomac.2017.07.076CrossRef

25.

Das S, Ghosh S, De AK, Bera T (2017) Oral delivery of ursolic acid-loaded nanostructured lipid carrier coated with chitosan oligosaccharides: development, characterization, in vitro and in vivo assessment for the therapy of leishmaniasis. Int J Biol Macromol 102:996–1008. https://doi.org/10.1016/j.ijbiomac.2017.04.098CrossRef

26.

Asthana S, Jaiswal AK, Gupta PK et al (2013) Immunoadjuvant chemotherapy of visceral leishmaniasis in hamsters using amphotericin B-encapsulated nanoemulsion template-based chitosan nanocapsules. Antimicrob Agents Chemother 57:1714–1722. https://doi.org/10.1128/AAC.01984-12CrossRef

27.

Costa Lima SA, Resende M, Silvestre R et al (2012) Characterization and evaluation of BNIPDaoct-loaded PLGA nanoparticles for visceral leishmaniasis: in vitro and in vivo studies. Nanomedicine 7:1839–1849. https://doi.org/10.2217/nnm.12.74CrossRef

28.

Asthana S, Gupta PK, Jaiswal AK et al (2015) Targeted chemotherapy of visceral leishmaniasis by lactoferrin-appended amphotericin B-loaded nanoreservoir: in vitro and in vivo studies. Nanomedicine 10:1093–1109. https://doi.org/10.2217/nnm.14.182CrossRef

29.

Tiwari B, Pahuja R, Kumar P et al (2017) Nanotized curcumin and miltefosine, a potential combination for treatment of experimental visceral leishmaniasis. Antimicrob Agents Chemother 61(3):e01169-16. https://doi.org/10.1128/AAC.01169-16

30.

Gupta PK, Jaiswal AK, Asthana S et al (2015) Self assembled ionically sodium alginate cross-linked amphotericin B encapsulated glycol chitosan stearate nanoparticles: applicability in better chemotherapy and non-toxic delivery in visceral leishmaniasis. Pharm Res 32:1727–1740. https://doi.org/10.1007/s11095-014-1571-4CrossRef

31.

Asthana S, Gupta PK, Jaiswal AK et al (2015a) Overexpressed macrophage mannose receptor targeted nanocapsules- mediated cargo delivery approach for eradication of resident parasite: in vitro and in vivo studies. Pharm Res 32: 2663–2677. https://doi.org/10.1007/s11095-015-1651-0

32.

Ray L, Karthik R, Srivastava V et al (2021) Efficient antileishmanial activity of amphotericin B and piperine entrapped in enteric coated guar gum nanoparticles. Drug Deliv Transl Res 11:118–130. https://doi.org/10.1007/s13346-020-00712-9CrossRef

33.

Ghosh S, Kar N, Bera T (2016) Oleanolic acid loaded poly lactic co- glycolic acid- vitamin E TPGS nanoparticles for the treatment of Leishmania donovani infected visceral leishmaniasis. Int J Biol Macromol 93:961–970. https://doi.org/10.1016/j.ijbiomac.2016.09.014CrossRef

34.

Kansal S, Tandon R, Dwivedi P et al (2012) Development of nanocapsules bearing doxorubicin for macrophage targeting through the phosphatidylserine ligand: a system for intervention in visceral leishmaniasis. J Antimicrob Chemother 67:2650–2660. https://doi.org/10.1093/jac/dks286CrossRef

35.

Jesus JA, Sousa IMO, da Silva TNF et al (2021) Preclinical assessment of ursolic acid loaded into nanostructured lipid carriers in experimental visceral leishmaniasis. Pharmaceutics 13:908. https://doi.org/10.3390/pharmaceutics13060908CrossRef

36.

Lopes RM, Gaspar MM, Pereira J et al (2014) Liposomes versus lipid nanoparticles: comparative study of lipid-based systems as oryzalin carriers for the treatment of leishmaniasis. J Biomed Nanotechnol 10:3647–3657. https://doi.org/10.1166/jbn.2014.1874CrossRef

37.

Thapa R, Mondal S, Riikonen J et al (2021) Biogenic nanoporous silicon carrier improves the efficacy of buparvaquone against resistant visceral leishmaniasis. PLoS Negl Trop Dis 15:e0009533. https://doi.org/10.1371/journal.pntd.0009533CrossRef

38.

Asthana S, Jaiswal AK, Gupta PK et al (2015) Th-1 biased immunomodulation and synergistic antileishmanial activity of stable cationic lipid–polymer hybrid nanoparticle: biodistribution and toxicity assessment of encapsulated amphotericin B. Eur J Pharm Biopharm 89:62–73. https://doi.org/10.1016/j.ejpb.2014.11.019CrossRef

39.

Ghosh S, Das S, De AK et al (2017) Amphotericin B-loaded mannose modified poly(D, L-lactide-co-glycolide) polymeric nanoparticles for the treatment of visceral leishmaniasis: in vitro and in vivo approaches. RSC Adv 7:29575–29590. https://doi.org/10.1039/C7RA04951JCrossRef

40.

Silva DF, Reis LES, Machado MGC et al (2021) Repositioning of tamoxifen in surface-modified nanocapsules as a promising oral treatment for visceral leishmaniasis. Pharmaceutics 13:1061. https://doi.org/10.3390/pharmaceutics13071061CrossRef

41.

Parvez S, Yadagiri G, Gedda MR et al (2020) Modified solid lipid nanoparticles encapsulated with Amphotericin B and Paromomycin: an effective oral combination against experimental murine visceral leishmaniasis. Sci Rep 10:12243. https://doi.org/10.1038/s41598-020-69276-5CrossRef

42.

Chaurasia M, Pawar VK, Jaiswal AK et al (2015) Chondroitin nanocapsules enhanced doxorubicin induced apoptosis against leishmaniasis via Th1 immune response. Int J Biol Macromol 79:27–36. https://doi.org/10.1016/j.ijbiomac.2015.04.043CrossRef

43.

Kansal S, Tandon R, Verma A et al (2014) Coating doxorubicin-loaded nanocapsules with alginate enhances therapeutic efficacy against L eishmania in hamsters by inducing Th1-type immune responses. Br J Pharmacol 171:4038–4050. https://doi.org/10.1111/bph.12754CrossRef

44.

Xu R (2008) Progress in nanoparticles characterization: sizing and zeta potential measurement. Particuology 6:112–115. https://doi.org/10.1016/j.partic.2007.12.002CrossRef

45.

Habanjar O, Diab-Assaf M, Caldefie-Chezet F, Delort L (2021) 3D cell culture systems: tumor application, advantages, and disadvantages. Int J Mol Sci 22:12200. https://doi.org/10.3390/ijms222212200CrossRef

46.

Matai I, Kaur G, Seyedsalehi A et al (2020) Progress in 3D bioprinting technology for tissue/organ regenerative engineering. Biomaterials 226:119536. https://doi.org/10.1016/j.biomaterials.2019.119536CrossRef

Title: Nanoparticles for the treatment of visceral leishmaniasis: review
Authors: Natália Silva de Santana
Luciana Betzler de Oliveira de Siqueira
Tatielle do Nascimento
Ralph Santos-Oliveira
Ana Paula dos Santos Matos
Eduardo Ricci-Júnior
Publication date: 01-02-2023
Publisher: Springer Netherlands
Published in: Journal of Nanoparticle Research / Issue 2/2023
Print ISSN: 1388-0764
Electronic ISSN: 1572-896X
DOI: https://doi.org/10.1007/s11051-023-05676-8

Springer Professional

Abstract

Graphical Abstract

Please log in to get access to your license.

Dont have a licence yet? Then find out more about our products and how to get one now:

Springer Professional "Wirtschaft+Technik"

Springer Professional "Technik"

Other articles of this Issue 2/2023

Nanoparticle and nanomaterial involvement during the wound healing process: an update in the field

Eudragit®-based nanoparticles for controlled release through topical use

Three-dimensional open concave surface-enhanced Raman scattering sensor based on the SiO2/CNTs/AgNPs to detect the phenol red

Chitosan/tripolyphosphate nanoparticle as elastase inhibitory peptide carrier: characterization and its in vitro release study

Mechanistic insights into the simultaneous visible-light induced photodegradation of organic pollutants by g-C3N4/titanate heterojunction

Copper nitride/silver nanostructures synthesized via wet chemical reduction method for the oxygen reduction reaction

Premium Partners